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Abstract
Background: The Metabolic syndrome (MS) which is a constellation of cardiometabolic risk factors including
dyslipidaemia, hypertension, hyperglycaemia, central obesity, and endothelial dysfunction was hitherto relatively
uncommon among Africans south of the Sahara. This study seeks to determine the prevalence of MS, its
components and risk factors among a rural population in Ghana based on two popular international algorithms.
Methods: This was a cross-sectional survey of a rural population in Ghana conducted between November and
December, 2007. Two hundred and twenty-eight (228) settler farmers, families and staff associated with the GOPDC
Ltd, between the ages of 35 and 64 years, were randomly selected for the study; pregnant women were excluded.
The prevalence of MS was estimated using the IDF and ATPIII criteria.
Results: The final subject pool included 102 males, and 104 females. The mean age of all subjects was 44.4 ± 6.9 years.
The overall prevalence of MS by the IDF and ATPIII criteria were 35.9% and 15.0%, respectively, but there was an
alarming female preponderance by both criteria {IDF: males = 15.7%, females =55.8%; ATPIII: males = 5.9%,
females = 24.0%; sex differences p<0.001 for both criteria}. The most important determinants for IDF-defined MS
were central obesity (55.3%), low High Density Lipoprotein (42.7%) and high Blood Pressure (39.5%).
Conclusion: The triad of central obesity, high blood pressure and low HDL were most responsible for the syndrome in
this rural population.
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Background
Metabolic syndrome (MS) which hitherto was relatively
uncommon among Africans south of the Sahara, is in-
creasingly becoming a public health concern in recent
times [1]. Several authors have referred to MS by different
synonyms prominent among which are Reaven’s Syn-
drome, Syndrome X, Insulin Resistance Syndrome, Deadly
Quartet and Hypertriglyceridemic Waist [2-5]. The syn-
drome is a constellation of cardiometabolic risk factors in-
cluding dyslipidaemia, hypertension, hyperglycaemia,
central obesity, and endothelial dysfunction [6-10]. MS
predisposes individuals to increased risk of cardiovascular
disease and type 2 diabetes mellitus and their attendant
complications such as heart attack, stroke and renal dis-
ease [11,12].
Several criteria have evolved in defining the syndrome.
In 1998, the World Health Organisation (WHO) pub-
lished the first working definition of MS with emphasis
on insulin resistance. Subsequently, the European Group
for the Study of Insulin Resistance (EGIR) proposed a
modification to that of the WHO. The EGIR criterion
still required evidence of insulin resistance but added
greater focus on abdominal obesity. In 2001, the National
Cholesterol Education Programme (NCEP) Adult Treat-
ment Panel III (ATP III) released its definition for MS,
de-emphasizing insulin resistance. Subsequently in 2003,
the American Association of Clinical Endocrinologists
(AACE) modified the NCEP ATP III criterion to refocus
on insulin resistance as the primary cause of metabolic
risk factors. In the wake of the varied algorithms for MS
and consequential confusion in comparing epidemio-
logical studies, the International Diabetic Federation
(IDF) in 2005 provided a clinical algorithm for MS that* Correspondence: mawuli_gyakobo@yahoo.com1Ghana-Michigan Charter, C/O Office of the Provost, College of Health
Sciences, University of Ghana, P. O. Box KB 52, Korle-Bu, Ghana
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attempts to accommodate the different diagnostic criteria
and ethnic differences [5,8,10,13].
High prevalence rates of over 40% have been docu-
mented by the IDF criterion in Portugal, Mexico, Urban
China, and the United Arab Emirates. India and Brazil
also recorded rates above 40% by the NCEP ATP III
criterion. Low rates below 10% by both the NCEP
ATP III and IDF criteria have been reported in Spain,
Japan and Hong Kong [3,6,14], underscoring inter-
national variations by both algorithms. Epidemiological
studies have reported differences in prevalence rates
between males and females in the US [8,15] and Iran
[2,11] bringing to the fore the sex sensitivity of both
algorithms.
Studies on the MS in sub-Saharan Africa is scanty [1].
Epidemiologic studies in rural Nigeria reported a preva-
lence rate of 12.1% by the NCEP ATP III criterion but
noted similar prevalence rate between males and females
[16]. In Ghana, the prevalence and determinants of the
MS have not yet been studied in rural communities. This
study documents the epidemiology of MS and it’s com-
ponents in rural Ghanaian males and females, using the
NCEP ATP III and IDF international algorithms for MS.
Methods
Subjects
This was a cross-sectional survey of a rural population
in Ghana conducted from November to December 2007.
In arriving at the sample size, an assumed prevalence
rate of 50% was used since there was no record of any
study on MS in the country. At 95% confidence interval
and the degree of accuracy set to 0.05, the desired sam-
ple size came to 384. Excluding pregnant women, hyper-
tensives, diabetics, persons not willing to participate in
the study and others who were on vacation or could not
be traced during the period of the study, the sample size
reduced to 228. The subjects included settler farmers,
families and staff associated with the Ghana Oil Palm
Development Company Limited (GOPDC Ltd), between
the ages of 35 and 64 years. Subjects were randomly
selected from the staff list in the accounts office and
nominal roll in the Human Resource Unit of the Com-
pany. Randomisation was facilitated by coded tally cards.
Data for 22 subjects out of the 228 were incomplete and
discarded as a result of insufficient blood samples.
Measurements
Two professional nurses were trained on the structured
interview guide for the survey. The interview guide was
divided into three sections: socio-demographic factors,
anthropometric measures and biochemistry.
The interview guide gathered information on demo-
graphic factors like age, gender and educational back-
ground; risk factors of chronic diseases such as smoking,
alcohol intake, diet and physical exercise; prevalence of
chronic diseases including hypertension, diabetes melli-
tus, and dyslipideamia.
The anthropometric measures taken included height,
body weight measured in the upright position to the
nearest 0.5cm and 0.1kg respectively. The waist circum-
ference (WC) measurements were taken at the end of a
normal expiration to the nearest 0.1cm, measuring at
the midpoint between the subcostal plane and the supra-
cristal plane.
Mercury sphygmomanometers were used to measure
the blood pressure of each subject in the sitting position
after 30 minutes of rest. Subjects were asked to refrain
from smoking, or ingesting alcohol and caffeine contain-
ing products a day before the survey. Three readings
each of systolic and diastolic blood pressures were
recorded per subject with an interval of five minutes at
the least and the mean was used for the data analysis.
Ethical review and ethics in human subjects research
Ethical approval for this study was given by the Ghana
Health Service Ethics Review Committee. Reviewers
from the West African College of Physicians have also
reviewed the research protocol and granted permission
for its execution in fulfilment of requirements towards
the award of a Fellowship in Family Medicine. Adminis-
trative permission was granted by St. Dominic’s Hospital
and the Ghana Oil Palm Development Company where
the research was carried out.
All respondents voluntarily participated after the intent
and the design of the study had been explained to them
and signing informed consent forms prior to implementa-
tion of the study.
Biochemical analysis
Blood sampling was done on the mornings of six Saturdays
in the months of November and December 2007 among
subjects who had completed the first and second sections
of the interview guide. Announcement was made through
the community using a public address system the evening
preceding blood sampling. Samples were obtained from
antecubital veins using 10ml syringes after an overnight
fast (10 – 16 hours). Samples for fasting plasma glucose
were collected into sodium fluoride/K3EDTA bottles and
that for fasting lipids were collected into vacutainer serum
separated tubes.
Blood samples were immediately analysed for fasting
blood glucose using glucometer (“onetouch ultra”) and
subjects found to be having abnormal readings were
referred to the hospital. Urine samples were also collected
and immediately analysed using the 10 parameter test
strip. Urine ketones, glucose and proteins were among the
parameters under investigation.
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The remaining samples were packaged into ice
chests and transported to the biochemistry laboratory
of St. Dominic’s Hospital (SDH), Akwatia. Samples for
fasting glucose and lipid were centrifuged at 5000RPM
for 2 minutes and the supernatant plasma and serum
respectively collected into plane eppendorf bottles.
These were frozen and stored at 4°C.
Samples were collected in duplicate and one set was
analysed in SDH whiles the second set was transported
in an ice chest to the research laboratory in Korle-Bu
Teaching Hospital, Accra within 24 hours for repeat
biochemical analysis.
Fasting plasma glucose (FPG) was determined using
the enzymatic photometric test according to Barham
and Trinder via the “smartlab auto-analyser”. Fasting
lipid profile including triglycerides (TG), high density
lipoprotein (HDL), low density lipoprotein (LDL), and
total cholesterol (TC) were also estimated using the
“smartlab auto-analyser”.
TG was measured by the colorimetric enzymatic
test using glycerol-3-phosphate-oxidase with the aid of
the auto-analyser. HDL was determined after the pre-
cipitation of chylomicrons, very low density lipopro-
teins and low density lipoproteins. Centrifugation left
only HDL in the supernatant which was determined
enzymatically. Total cholesterol was determined by
the enzymatic photometric test. LDL was computed,
thus:
LDL ¼ TC  HDLþ TG  5ð Þ
Diagnostic criteria for metabolic syndrome (MS)
The diagnostic criteria for the MS are listed as follows:
International Diabetes Federation (IDF) criterion:
WC ≥ 94cm in men or ≥80cm in women plus two
or more of the following:
a. Low HDL = HDL <40mg/dl in males or <50mg/dl
in females, or specific treatment for this lipid
abnormality
b. Hypertriglyceridaemia = TG≥150mg/dl, or specific
treatment for this lipid abnormality
c. Hypertension = SBP ≥130mmHg or
DBP≥85mmHg, or treatment for previously
diagnosed hypertension
d. Dysglycaemia = FPG≥100mg/dl, or previously
diagnosed type 2 diabetes
National Cholesterol Education Program Adult
Treatment Panel (NCEP ATP III) criterion:
At least three of the following criteria:
a. Obesity = WC>102cm in men and 88cm in
women
b.Hypertrigylceridaemia = TG≥150mg/dl
c. Low HDL = HDL<40mg/dl in men and <50mg/dl
in women
d.Hypertension = BP≥130/85mmHg
e. Dysglycaemia = FPG ≥110mg/dl
Statistical analysis
Data was analysed using the Statistical Package for Social
Sciences, version 15.0 software (SPSS Inc., Chicago, Illinois,
USA). Continuous variables were expressed as means and
standard deviations and discrete variables were presented
as proportions. The prevalence of the metabolic syndrome
(MS) among males and females was determined. Age-
specific prevalence rates of MS and its components were
also determined.
The chi-squares test was performed to test for differ-
ences in proportions of categorical variables between
two or more groups. In 2*2 tables, the Fisher exact test
(2-tailed) replaced the chi-squared test if the assump-
tions underlying chi-squared were violated, such as
situations of small sample size and where the expected
frequency is less than 5 in any of the cells.
Multinomial logistic regression analysis was used to
determine the type and degree of association between
MS and its socio-demographic and behavioural risk fac-
tors. The result is presented as odds ratios (ORs) to-
gether with their 95% confidence interval (95%CI). The
trend in ORs across MS risk factors was evaluated using
the likelihood ratio test.
The agreement between IDF and NCEP ATP III criteria
of MS was determined by the kappa statistics (k). The
level of agreement is considered poor with k≤0.20, fair
with k=0.21 to 0.40, moderate with k=0.41 to 0.60,
substantial with k=0.61 to 0.80, and very good with
k>0.80 [13]. P values of less than 0.05 were considered
statistically significant.
Results
Data on 206 subjects, 102 (49.5%) males and 104 (50.5%)
females were analysed. The socio-demographic and be-
havioural characteristics of the study population by sex
are provided in Table 1. There was a significant differ-
ence between males and females in terms of age
(p<0.001), marital status (p=0.001), family type (p=0.007),
educational status (p=0.011), occupation (p<0.001),
smoking (p=0.007), alcohol ingestion (p=0.001) and body
mass index (p<0.001). No significant difference was
observed between the sexes for insurance status. There
was a higher prevalence of younger subjects (52.0%) and
the females constituted the majority (65.0%). The popula-
tion was almost universally married (91.3%), especially
among males (98.0%). The family type was skewed to-
wards nuclear family (86.8%), and especially among
males (93.1%). Nearly 94.0% of the subjects had some
education.
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Table 1 Socio-demographic and behavioural characteristics of the study population by sex
Variable Male (%)a Female (%)a Total (%)a p
Age (Years) P<0.001
35 – 44 39 (38.6) 67 (65.0) 106 (52.0)
45 – 64 62 (61.4) 36 (35.0) 98 (48.0)
Total 101 (100.0) 103 (100.0) 204 (100.0)
Marital Status P=0.001
Singleb 2 (2.0) 16 (15.4) 18 (8.7)
Married 100 (98.0) 88 (84.6) 188 (91.3)
Total 102 (100.0) 104 (100.0) 206 (100.0)
Family Type P=0.007
Open Parent 1 (1.0) 12 (11.7) 13 (6.4)
Nuclear Family 94 (93.1) 83 (80.6) 177 (86.8)
Extended Family 6 (5.9) 6 (5.8) 12 (5.9)
Joint Family 0 (0.0) 2 (1.9) 2 (1.0)
Total 101 (100.0) 103 (100.0) 204 (100.0)
Educational Status P=0.011
No Education 2 (2.0) 11 (10.6) 13 (6.3)
Some Education c 100 (98.0) 93 (89.4) 193 (93.7)
Total 102 (100.0) 104 (100.0) 206 (100.0)
Insurance Status P=0.662
Insured 84 (82.4) 88 (84.6) 172 (83.5)
Uninsured 18 (17.6) 16 (15.4) 34 (16.5)
Total 102 (100.0) 104 (100.0) 206 (100.0)
Occupation p<0.001
Sedentary Office Worker 19 (18.6) 1 (1.0) 20 (9.7)
Active Office Worker 44 (43.1) 70 (67.3) 114 (55.3)
Field Worker 39 (38.2) 33 (31.7) 72 (35.0)
Total 102 (100.0) 104 (100.0) 206 (100.0)
Smoking p=0.007
Ever Smoker 15 (14.7) 4 (3.8) 19 (9.2)
Never Smoker 87 (85.3) 100 (96.2) 187 (90.8)
Total 102 (100.0) 104 (100.0) 206 (100.0)
Alcohol p=0.001
Ever Drinker 68 (67.3) 45 (43.3) 113 (55.1)
Never Drinker 33 (32.7) 59 (56.7) 92 (44.9)
Total 101 (100.0) 104 (100.0) 205 (100.0)
Body Mass Index (BMI/kgm-2)d p<0.001
< 25.00 72 (70.6) 46 (45.1) 118 (57.8)
25.00 – 29.99 29 (28.4) 27 (26.5) 56 (27.5)
≥ 30.00 1 (1.0) 29 (28.4) 30 (14.7)
Total 102 (100.0) 102 (100.0) 204 (100.0)
p-values (2-tailed): Expresses the degree of significance between the sexes for each category.
a Percentage in a column.
b Single: Never married + Ever married (Separated, Divorced, Widow, Widower).
c Some Education: Basic + Secondary + Tertiary.
d Normal weight, BMI= <25.00kgm-2; Overweight, BMI= 25.00 – 29.99; Obese, BMI= ≥ 30.00.
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Active office workers (Junior staff ) were the most
prevalent, 55.3% among the study subjects and there was
a female preponderance (67.3%). Smoking was rare, at
9.2%, and alcohol consumption was 55.1% prevalent
overall with a high male prevalence (67.3%). More than
half (57.8%) of the study subjects had normal weight; for
males this was true for 70.6%. The obese constituted less
than a fifth of the population, and 28.4% of females.
The basic characteristic of the study subjects by sex
are shown in Table 2. The mean age, BMI, and WC
were 44.40 ± 6.87 years, 25.15 ± 4.67kgm-2 and 89.94 ±
10.41cm respectively. The females were younger
(42.80 ± 6.18 years) and had higher values of BMI and
WC (26.81 ± 5.30 kgm-2 and 92.47 ± 11.30cm respect-
ively), and thus were more prone to overweight and
obesity. The differences in the means between males
and females by selected determinants (age, body mass
index, systolic blood pressure, diastolic blood pressure,
fasting plasma glucose, high density lipoprotein, trigly-
cerides) of MS were not significant.
Table 3 shows the prevalence of the MS and its deter-
minants by sex as defined by the IDF and NCEP ATP III
criteria. The global prevalence of the syndrome was
15.0% and 35.9% by the NCEP ATP III and IDF criteria,
respectively. The prevalence by the IDF criterion was
more than twice that of the NCEP ATP III criterion.
There was a female preponderance in both criteria {IDF
(male: female ratio= 1 : 3.6); NCEP ATP III (male : fe-
male ratio= 1 : 4.1)} and this trend was significant in
both criteria (p<0.001). The kappa statistics for the
agreement between the IDF and NCEP ATPIII criteria
was moderate {k= 0.446, p<0.001; (results not shown)}.
Central obesity (55.3%) was the most prevalent deter-
minant of MS by the IDF criterion followed by low HDL
(42.7%) and then high BP (39.5%). The NCEP ATP III
criterion showed HDL (42.7%) as the most prevalent fol-
lowed by high BP (39.5%) and central obesity (31.1%).
The sex difference in prevalence rates among the
determinants was only significant for central obesity and
low HDL by both criteria (p<0.001, p= 0.005 respectively
by both criteria). In both the IDF and NCEP ATP III,
central obesity in women and high BP in men were the
most common determinants and the triad of central
obesity, low HDL and high BP constituted the most
widespread combination of metabolic abnormalities de-
termining MS.
Table 4 presents the results of age-specific prevalence
of MS and its determinants by the IDF and NCEP ATP
III criteria. Within the male population, MS did not sig-
nificantly increase with age by either the IDF and NCEP
ATP III criteria (p= 0.679, p= 0.665, respectively). The
contrary was observed among the females by the IDF
criterion, for whom MS did increase with age (p=0.012).
High BP demonstrated significant increase in the trend
of MS with age for all three categories; all (p<0.001),
male (0.047), female (p<0.001) by both criteria. A similar
trend was seen in High TG except in the female group
(all: p=0.028, male: p=0.011, female: p=0.380 for both
criteria). On the contrary, prevalence of MS significantly
decreased with age among the males for High FPG
(p=0.020).
The predictive odds of MS (IDF criterion) with varia-
tions in socio-demographic and behavioural risk factors
are shown in Table 5. The younger age group of 35–44
years were 70.2% (95% CI= 0.125-0.714) less likely to de-
velop MS with reference to the older subjects (45–64
years), while males were 94.0% (95% CI= 0.020-0.178)
less likely to develop the syndrome compared to females.
The obese and overweight subjects were more than 5,
and 10 times, respectively {(95% CI: obese (1.780-
17.069), overweight (4.170-26.782)} more likely to de-
velop MS than normal weight subjects.
Discussion
This study was conducted among staff, relatives and set-
tler farmers associated with the GOPDC Ltd and thus
Table 2 Basic characteristics of study subjects by sex
Variables Mean ± Standard Deviation
All (n=206) Males (n=102) Females (n=104) p-values
Age (years) 44.40 ± 6.87 46.04 ± 7.17 42.80 ± 6.18 0.286
BMI (kgm-2) 25.15 ± 4.67 23.47 ± 3.15 26.81 ± 5.30 0.200
WC (cm) 89.94 ± 10.41 87.36 ± 8.75 92.47 ± 11.30 0.225
SBP (mmHg) 125.29 ± 16.97 124.66 ± 13.86 125.91 ± 19.59 0.554
DBP (mmHg) 83.35 ± 14.22 83.38 ± 12.29 83.32 ± 15.94 0.086
FPG (mg/dl) 81.01 ± 22.06 82.73 ± 26.02 79.41 ± 17.60 0.799
HDL (mg/dl) 50.47 ± 17.85 49.86 ± 16.53 51.05 ± 19.06 0.699
TG (mg/dl) 100.38 ± 43.81 97.32 ± 42.40 103.26 ± 45.13 0.176
p-values (2-tailed): Students T-test comparing the mean values between males and females of selected determinants of metabolic syndrome (MS); BMI: body mass
index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; HDL: high density lipoprotein;
TG: triglycerides.
Gyakobo et al. BMC Endocrine Disorders 2012, 12:25 Page 5 of 9
http://www.biomedcentral.com/1472-6823/12/25
Table 3 Prevalence of the metabolic syndrome (MS) and its determinants by sex as defined by the IDF and NCEP ATP
III criteria
Determinants
of MS
Prevalence of metabolic syndrome components (%)
IDF NCEP ATP III
All (206) Male (102) Female (104) p All (206) Male (102) Female (104) p-values
Central Obesity 55.3 22.5 87.5 <0.001 31.1 3.9 57.7 <0.001
High BP 39.5 39.0 40.0 0.896 39.5 39.0 40.0 0.896
High FPG 12.1 11.8 12.5 0.872 5.3 5.9 4.8 0.732
Low HDL-C 42.7 32.3 52.5 0.005 42.7 32.3 52.5 0.005
High TG 10.4 9.7 11.1 0.745 10.4 9.7 11.1 0.745
MS 35.9 15.7 55.8 <0.001 15.0 5.9 24.0 <0.001
p- Values (2-tailed): comparing males and females; Central Obesity= IDF {WC≥94cm in males, ≥80cm in females} and NCEP ATPIII {WC>102cm in males, >88cm in females}.
High BP= IDF and NCEP ATPIII {SBP≥130mmHg, DBP≥85mmHg}.
High FPG= IDF {FPG≥100mg/dl}, NCEP ATPIII {FPG≥110mg/dl}.
Low HDL-C= IDF and NCEP ATPIII {HDL <40mg/dl in males, <50mg/dl in females}.
High TG= IDF and NCEP ATPIII {TG≥150mg/dl}.
MS= IDF (International Diabetes Federation) {central obesity and at least two of the following: low HDL-C (or treatment for low HDL-C), high TG (or treatment for
high TG), high BP (or treatment for high BP) and high FPG (or treatment for high FPG)}.
MS= NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) { at least three of the following: central obesity, high TG, low HDL-C, high BP
and high FPG}.
Table 4 Age-specific prevalence of metabolic syndrome (MS) and its determinants by the IDF and NCEP ATPIII criteria
MS and
Determinants
Prevalence of determinants of metabolic syndrome by age and sex (%) a
IDF NCEP ATP III
All Male Female All Male Female
MS
35-44 34.0 12.8 46.3 14.2 2.6 20.9
45-64 36.7 16.1 72.2 16.3 8.1 30.6
P value b 0.679 0.649 0.012 0.665 0.255 0.276
Central Obesity
35-44 61.3 17.9 86.6 35.8 2.6 55.2
45-64 48.0 24.2 88.9 25.5 4.8 61.1
P value b 0.055 0.459 0.735 0.110 0.568 0.565
High BP
35-44 25.6 25.0 25.9 25.6 25.0 25.9
45-64 55.0 46.9 67.7 55.0 46.9 67.7
P value b <0.001 0.047 <0.001 <0.001 0.047 <0.001
High FPG
35-44 12.3 12.8 11.9 7.5 12.8 4.5
45-64 12.2 11.3 13.9 3.1 1.6 5.6
P value b 0.997 0.817 0.776 0.156 0.020 0.808
Low HDL
35-44 45.5 38.9 49.2 45.5 38.9 49.2
45-64 39.3 28.6 57.6 39.3 28.6 57.6
P value b 0.387 0.303 0.435 0.387 0.303 0.435
High TG
35-44 5.9 0.0 9.2 5.9 0.0 9.2
45-64 15.7 16.1 15.2 15.7 16.1 15.2
P value b 0.028 0.011 0.380 0.028 0.011 0.380
a Percentage of subjects in that age group out of studied subjects in the same age group.
b p-values (2-tailed) apply to the prevalence of the determinants of the metabolic syndrome across age groups.
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the findings cannot be generalized to all rural communi-
ties in Ghana. In spite of this, these findings are very im-
portant to the documentation of metabolic syndrome in
modern Ghana.
The prevalence of MS was alarmingly high {35.9%
(IDF) and 15.0% (NCEP ATP III)} in this rural commu-
nity of mainly farmers and small scale industrialist (oil
palm extraction). Earlier studies in Cameroon [17], and
Nigeria [18], both in West Africa, found much lower
prevalence rates. However, a study by Adegoke and
fellow researchers in Nigeria determined a rate of 12.7%
(NCEP ATP III) that was much close to findings in our
study [16]. Studies in the US [8,12,15] and Europe
[19-25] revealed higher rates but for a few [26-28] which
produced similar findings. This high prevalence rate in
Ghana cannot so easily be attributed to a presumed
westernization of diet and lifestyle, as these data emerge
from a rural, agrarian community with traditional reli-
ance on home-cooked foods, and a high burden of phys-
ical labour. Stress could be a major player in this
Table 5 Odds ratios of MS according to socio-demographic and behavioural risk factors; applying the IDF criterion
Variables N (%) p-value OR 95% CI
Age (years)
35 – 44 103 (51.8) 0.007 0.298 0.125 – 0.714
45 – 64 96 (48.2) Referent 1.0 Referent
Sex
Male 99 (49.7) <0.001 0.060 0.020 – 0.178
Female 100 (50.3) Referent 1.0 Referent
Marital Status
Married 181 (91.0) 0.698 0.598 0.045 – 8.000
Single 18 (9.0) Referent 1.0 Referent
Family Type
Joint Family 2 (1.0) 0.504 3.786 0.076 – 188.597
Open Parent 13 (6.5) 0.556 0.424 0.024 – 7.381
Extended Family 10 (5.0) 0.835 0.830 0.144 – 4.782
Nuclear Family 174 (87.4) Referent 1.0 Referent
Educational Status
Some Education 189 (95.0) 0.289 2.532 0.454 – 14.124
No Education 10 (5.0) Referent 1.0 Referent
Insurance Status
Uninsured 34 (17.1) 0.607 0.724 0.211 – 2.481
Insured 165 (82.9) Referent 1.0 Referent
Occupation
Active Office Worker 109 (54.8) 0.816 0.897 0.360 – 2.236
Sedentary Office Worker 20 (10.1) 0.118 3.270 0.739 – 14.470
Field Worker 70 (35.2) Referent 1.0 Referent
Smoking
Ever Smoked 17 (8.5) 0.649 0.701 0.152 – 3.241
Never Smoked 182 (91.5) Referent 1.0 Referent
Alcohol
Ever Drinker 111 (55.8) 0.670 0.840 0.377 – 1.871
Never Drinker 88 (44.2) Referent 1.0 Referent
Body Mass Index (kgm-2)
Obese (≥ 30) 28 (14.1) 0.003 5.512 1.780 – 17.069
Overweight (25.00 - 29.99) 55 (27.6) <0.001 10.568 4.170 – 26.782
Normal Weight (< 25.00) 116 (58.3) Referent 1.0 Referent
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circumstance by triggering a chain of neuroendocrine
events culminating in disturbed metabolism. Undocu-
mented environmental exposures or genetic factors may
be of research interest in the future.
The IDF criterion yielded a higher prevalence rate (2.4
times) than the NCEP ATP III and this may be due to
the lower cut-off points for WC and FPG. Similar trends
have been observed in other studies [6,8,27,29,30] but
the contrary is also been documented [11,14].
In spite of the differences observed in the prevalence
rates by the IDF and NCEP ATP III criteria, the agree-
ment between the two algorithms was moderate, 0.45 as
alluded to by Choi and co-workers [31]. Several other
studies yielded substantial to very good agreement be-
tween the two algorithms [11,13,25,26,32].
There was a significant sex difference in the preva-
lence of MS in this population. The prevalence was
approximately four times higher among females by
both algorithms and this is in consonance with other
studies with similar, though relatively less dramatic,
sex differentials [11,26,31]. The inverse was found by
Alegria and fellow researchers [33]. This difference
may be due to the significant and higher prevalence of
overweight and obese females (55.0%) than males
(29.0%) in our study, but more attention is warranted
given the likely negative public health implications of
these rates among females.
The triad of low HDL, high BP, and central obesity
were largely responsible for MS in this community.
This combination was also observed in Nigeria [18]
and the US [12]. High BP and central obesity were the
most prevalent determinants among males and females
respectively and this is corroborated by studies in
Sweden [28], the US [12], the Hong Kong, Chinese and
Hungarian populations [30,34]. This development prob-
ably predicts how the two sexes cope with stress.
The prevalence of MS increased with age [6,19] but
reached the level of significance only for females (IDF).
This trend is supported by findings in the regression
analysis where the younger age group (35–44 years)
was 70% less likely to develop MS compared to the
older group (45–64 years) and age effects could be
due to the significant and positive correlation between
SBP and DBP with age (results not shown). Hypertri-
glyceridaemia was also significantly increased with age
except for the females and this may be partly due to
the positive and significant correlation between age
and triglycerides (results not shown). In consonance
with the expected, “sedentary office workers” were
more than thrice likely to develop MS with reference
to “field workers” whiles the contrary was observed for
“active office workers” but these findings did not reach
the level of significance. Additionally, subjects with
“some education” were more than twice likely to
develop MS than subjects with “no education” and this
also did not reach the level of significance.
Conclusion
In conclusion, the prevalence of an MS diagnosis was
alarmingly high among this population of women in
rural Ghana, despite high physical workloads. Consist-
ent with experience elsewhere, the IDF algorithm identi-
fied twice as many subjects as having MS, compared to
the NCEP ATP III algorithm. The triad of central obes-
ity, high blood pressure and low HDL were most re-
sponsible for the syndrome in this rural population.
Younger age, male sex, and normal weight were protect-
ive against MS. This study needs to be extended to
other parts of the country to ascertain the national
prevalence rate vis-à-vis, its rural–urban distribution.
There is the additional need to determine whether these
diagnostic standards are indeed associated with poor
long-term clinical outcomes as they are in other parts
of the world.
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